Compare DRTS & IRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DRTS | IRMD |
|---|---|---|
| Founded | 2015 | 1992 |
| Country | Israel | United States |
| Employees | 121 | 166 |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | N/A | 2014 |
| Metric | DRTS | IRMD |
|---|---|---|
| Price | $13.15 | $92.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $8.67 | ★ $116.00 |
| AVG Volume (30 Days) | ★ 553.0K | 109.3K |
| Earning Date | 05-18-2026 | 05-01-2026 |
| Dividend Yield | N/A | ★ 0.95% |
| EPS Growth | N/A | ★ 16.67 |
| EPS | N/A | ★ 0.86 |
| Revenue | N/A | ★ $83,814,000.00 |
| Revenue This Year | N/A | $12.38 |
| Revenue Next Year | $699.98 | $11.31 |
| P/E Ratio | ★ N/A | $106.06 |
| Revenue Growth | N/A | ★ 14.43 |
| 52 Week Low | $3.01 | $67.84 |
| 52 Week High | $14.11 | $107.90 |
| Indicator | DRTS | IRMD |
|---|---|---|
| Relative Strength Index (RSI) | 57.08 | 42.18 |
| Support Level | $11.24 | $90.96 |
| Resistance Level | $14.00 | $97.63 |
| Average True Range (ATR) | 0.80 | 3.10 |
| MACD | -0.02 | -0.50 |
| Stochastic Oscillator | 69.05 | 18.99 |
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.
iRadimed Corp develops, manufactures, markets, and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system, which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates the majority revenue from United States.